Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and accounts for more than 90% of primary liver cancer. The advent of immune checkpoint inhibitor (ICI)-related therapies combined with angiogenesis inhibition has revolutionized the treatment of HCC in late-stage and unre...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2024-02-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1324140/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|